贝伐珠单抗联合卡铂-培美曲塞化疗联合或不联合阿替利珠单抗一线治疗晚期胸膜间皮瘤的随机III期研究:ETOP 13-18 BEAT-meso试验结果
BEAT-meso是一项国际开放标签1:1随机III期试验,纳入400例晚期弥漫性胸膜间皮瘤患者,比较贝伐珠单抗+卡铂-培美曲塞化疗联合或不联合阿替利珠单抗一线治疗。主要终点OS未达统计学显著(20.5 vs 18.1个月,HR 0.84,P=0.14),但PFS显著延长(9.2 vs 7.6个月,HR 0.72,P=0.0021),非上皮样亚型OS获益显著(HR 0.51)。
要点
- ABC组中位OS 20.5个月 vs BC组18.1个月,HR 0.84(95%CI 0.66-1.06),P=0.14,主要终点未达到。
- ABC组中位PFS 9.2个月 vs BC组7.6个月,HR 0.72(95%CI 0.59-0.89),P=0.0021,差异显著。
- 非上皮样亚型OS HR 0.51(95%CI 0.32-0.80),上皮样亚型OS HR 1.01(95%CI 0.77-1.32),交互作用P=0.012。
核心结论
- ABC较BC显著延长中位PFS,但中位OS数值增加未达统计学显著,主要终点未达到。
- 预设组织学分析中,非上皮样病例接受ABC的OS和PFS均更优。
研究设计与样本
- BEAT-meso为国际、开放标签、1:1随机III期试验,按组织学和分期分层。
- 2019年4月30日至2022年3月7日随机400例晚期弥漫性胸膜间皮瘤患者,每组200例。
- ABC组:阿替利珠单抗1200 mg每3周直至进展,贝伐珠单抗15 mg/kg每3周直至进展,卡铂AUC联合培美曲塞500 mg/m2每3周共4-6周期;BC组为贝伐珠单抗联合卡铂-培美曲塞。
主要发现
- 65%患者ECOG体力状态为1,78%为上皮样组织学。
- 中位随访35个月(数据截止2023年9月1日),ABC组中位OS 20.5个月 vs BC组18.1个月,HR 0.84(95%CI 0.66-1.06),P=0.14。
- ABC组中位PFS 9.2个月 vs BC组7.6个月,HR 0.72(95%CI 0.59-0.89),P=0.0021,差异显著。
- 组织学与治疗交互作用显著:非上皮样OS HR 0.51(95%CI 0.32-0.80),上皮样OS HR 1.01(95%CI 0.77-1.32),交互作用P=0.012。
- ≥3级治疗相关不良事件ABC组55% vs BC组47%;ABC组生活质量维持,与BC组无临床意义差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The currently approved first-line treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or platinum-pemetrexed. The addition of bevacizumab to chemotherapy improves overall survival (OS). While single-agent immunotherapy or chemotherapy-immunotherapy combinations are superior to chemotherapy monotherapy, there is a potential for synergistic triple combination of chemotherapy, bevacizumab, and immunotherapy. PATIENTS AND METHODS: BEAT-meso is an international, open-label, 1 : 1 randomised, phase III trial, with stratification factors histology and stage aiming to determine the efficacy and safety of adding atezolizumab [1200 mg, 3-week cycle (q3w) until progression] to bevacizumab (15 mg/kg, q3w until progression) and standard chemotherapy (4-6 cycles of carboplatin area under the curve with pemetrexed 500 mg/m2, q3w; ABC versus BC) as first-line treatment for advanced DPM. The primary endpoint is OS in all randomised patients, aiming for a relative benefit of 29% [hazard ratio (HR) 0.708]. Secondary endpoints include progression-free survival (PFS), adverse events (AEs), and symptom-specific and global quality of life (QoL). RESULTS: Between 30 April 2019 and 7 March 2022, 400 patients were randomised, 200 per arm. Sixty-five percent had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 and 78% had epithelioid histology. At a median follow-up of 35 months (data cut-off 1 September 2023), the median OS was 20.5 months for ABC versus 18.1 months for BC [HR 0.84, 95% confidence interval (CI) 0.66-1.06, P = 0.14]. Median PFS was significantly longer for ABC than for BC (9.2 versus 7.6 months) (HR 0.72, 95% CI 0.59-0.89, P = 0.0021). Histology showed significant treatment interaction for both PFS and OS, with an OS HR of 0.51 (95% CI 0.32-0.80) for non-epithelioid and 1.01 (95% CI 0.77-1.32) for epithelioid (interaction P = 0.012). Grade ≥3 treatment-related AEs were reported in 55% of patients in ABC and 47% in BC; QoL was maintained with ABC with no clinically meaningful differences from BC. CONCLUSIONS: The significant benefit in median PFS for ABC found in this study translated into a numerical but not significant increase in median OS. Thus, the primary endpoint was not met. In the pre-specified analysis by histology, superior OS and PFS were found for ABC in non-epithelioid cases.
引用
- Felip E, Popat S, Dafni U, et al. A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. Ann Oncol. 2025. PMID: 39814199. doi:10.1016/j.annonc.2024.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。